Diabetes

PUBLISHER: 360iResearch | PRODUCT CODE: 1318824

PUBLISHER: 360iResearch | PRODUCT CODE: 1318824

Type 1 Diabetes Drug Market by Form (Insulin Therapy, Oral Medication), End User (Drugstore, Hospital) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

PUBLISHED: June 12, 2023

PAGES: 182 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Global Type 1 Diabetes Drug Market is forecasted to grow significantly, with a projected USD 17.57 billion in 2023 at a CAGR of 9.04% and expected to reach a staggering USD 32.24 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Type 1 Diabetes Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Type 1 Diabetes Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Form, market is studied across Insulin Therapy and Oral Medication. The Insulin Therapy is further studied across Long-Acting Insulin, Premix Analogs, and Rapid Acting Insulin. The Oral Medication is further studied across Biguanides and Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. The Biguanides is further studied across Metformine and Metformine Extended-Release. The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors is further studied across Canaglifozine, Dapagliflozine, Empagliflozine, and Ertugliflozine. The Insulin Therapy is projected to witness significant market share during forecast period.

Based on End User, market is studied across Drugstore and Hospital. The Hospital is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Type 1 Diabetes Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Type 1 Diabetes Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 1 Diabetes Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 1 Diabetes Drug Market?

4. What is the competitive strategic window for opportunities in the Global Type 1 Diabetes Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Type 1 Diabetes Drug Market?

6. What is the market share of the leading vendors in the Global Type 1 Diabetes Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Type 1 Diabetes Drug Market?

Product Code: MRR-43676CF429F6

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Type 1 Diabetes Drug Market, by Form, 2022 vs 2030
4.3. Type 1 Diabetes Drug Market, by End User, 2022 vs 2030
4.4. Type 1 Diabetes Drug Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing incidences of type 1 diabetes globally
  - 5.1.1.2. Increasing healthcare expenditure with rising disposable income
  - 5.1.1.3. Rising patient awareness on type 1 diabetes treatment
- 5.1.2. Restraints
  - 5.1.2.1. Patent expiration of drugs
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging introduction of novel drugs to treat diabetes
  - 5.1.3.2. Surge in research and development activities for type 1 anti-diabetic drugs
- 5.1.4. Challenges
  - 5.1.4.1. Strict regulations for the approval drugs
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Type 1 Diabetes Drug Market, by Form

6.1. Introduction
6.2. Insulin Therapy
- 6.2.1. Long-Acting Insulin
- 6.2.2. Premix Analogs
- 6.2.3. Rapid Acting Insulin
6.3. Oral Medication
- 6.3.1. Biguanides
  - 6.3.1.1. Metformine
  - 6.3.1.2. Metformine Extended-Release
- 6.3.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  - 6.3.2.1. Canaglifozine
  - 6.3.2.2. Dapagliflozine
  - 6.3.2.3. Empagliflozine
  - 6.3.2.4. Ertugliflozine

7. Type 1 Diabetes Drug Market, by End User

7.1. Introduction
7.2. Drugstore
7.3. Hospital

8. Americas Type 1 Diabetes Drug Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Type 1 Diabetes Drug Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Type 1 Diabetes Drug Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing

Product Code: MRR-43676CF429F6

LIST OF FIGURES

FIGURE 1. TYPE 1 DIABETES DRUG MARKET RESEARCH PROCESS
FIGURE 2. TYPE 1 DIABETES DRUG MARKET SIZE, 2022 VS 2030
FIGURE 3. TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2022 VS 2030 (%)
FIGURE 5. TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 6. TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 7. TYPE 1 DIABETES DRUG MARKET DYNAMICS
FIGURE 8. TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 15. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

TABLE 1. TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 5. TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 6. TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 11. TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 13. TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 17. TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 45. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 46. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 48. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 49. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 51. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 52. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 53. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 54. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 77. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 78. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 79. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 80. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 83. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 84. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 85. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 86. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 95. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 96. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 97. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 98. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 101. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 107. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 108. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 113. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 114. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 119. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 120. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 125. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 126. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 131. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 132. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 133. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 134. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 137. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 138. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 150. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 151. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 152. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 153. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 156. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 157. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 158. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 159. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 162. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 163. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 164. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 165. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 168. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 169. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 170. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 171. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 174. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 175. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 176. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 177. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 186. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 187. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 188. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 189. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 198. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 199. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 204. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 205. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 206. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 207. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 210. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 211. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 212. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 213. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 216. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 217. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 218. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 219. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 240. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 241. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 242. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 243. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 258. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 259. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 260. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 261. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 270. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 276. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2022
TABLE 277. TYPE 1 DIABETES DRUG MARKET LICENSE & PRICING

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ